ImmunAdd develops innovative and practical solutions for human health. We aim to harness the immune system to create next-generation immunotherapeutics for the treatment of infectious diseases and cancer. Our next-generation adjuvants provide better immune activities in combination with anti-infection and anti-cancer vaccines. ImmunAdd has developed an efficient and sustainable manufacturing process for IA-05. With POC purpose, ImmunAdd will continue to expand our development to clinical-stage programs.
•IA-05 is our proprietary saponin-based vaccine adjuvant.
•IAS-01 is a liposome formulation of Toll-like receptor agonist and IA-05 which is a mimic of AS01.
•IA-C01 is a proprietary adjuvanted vaccine (not disclosed).
•IA-38 is the immune-stimulating/small molecular drug conjugation for cancer treatment.